Our findings suggest that clinically significant OATP1B-mediated interactions are not anticipated with CDK4/6 inhibitors, either as victims or perpetrators, which supports ongoing clinical trials investigating the co-administration of CDK4/6 inhibitors with OATP1B substrates and inhibitors.

15 days ago

Preclinical • Journal

HER-2 (Human epidermal growth factor receptor 2)

HER-2 negative

paclitaxel • Kisqali (ribociclib) • simvastatin

27d

Super-Resolution Microscopy Reveals Nanoscale Arrangement of PD-L1 Immune Checkpoint. (PubMed, Chem Biomed Imaging)

Further, treatments with drugs such as IFN-γ, 2-DG, and simvastatin modulate the density of PD-L1 without affecting its monomeric state...Finally, we observed that PD-L1 forms nanoclusters at cell-cell conjugation sites between breast cancer cells and T cells. Overall, these findings based on STORM extend our understanding of the nanoscale organization of PD-L1 on the membrane.

27 days ago

Journal

PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma)

simvastatin

Assembly Module-Empowering Lipid-Prodrug Nanoamplifier for Enhancing Ferroptosis-Driven Cancer Treatment. (PubMed, Nano Lett)

To address this limitation, we developed a lipid-prodrug nanoamplifier (SIM-SS-LA NAs), composed of disulfide-linked linoleic alcohol and simvastatin (SIM) to enhance ferroptosis...Notably, the released LA acts as an exogenous substrate, substantially increasing lipid peroxide accumulation and synergizing with SIM-mediated GPX4 inhibition to amplify ferroptosis. As expected, the lipid-prodrug nanoamplifier showed potent ferroptosis-driven antitumor activity in a 4T1 breast tumor-bearing mouse model, offering an efficient nanotherapeutic strategy for ferroptosis-based cancer therapy.

1 month ago

Journal

GPX4 (Glutathione Peroxidase 4)

simvastatin

Mechanisms of Qibai Pingfei Capsules in inhibiting pyroptosis of pulmonaryartery adventitial fibroblasts via regulating NLRP3/Caspase-1/ GSDMD pathway to intervene in COPD complicated by pulmonary arterial hypertension (PubMed, Zhongguo Zhong Yao Za Zhi)

Rats were divided into five groups(n=15 each), i.e., control, model, QBPF, QBPF + nigericin(NLRP3 activator), and simvastatin groups...In conclusion, QBPF attenuates lung function decline, suppresses inflammatory responses, alleviates pulmonary vascular remodeling, and intervenes in the disease progression of COPD complicated by PH in rats. Its mechanisms may be related to modulating the NLRP3/Caspase-1/GSDMD pathway to inhibit PAAF pyroptosis.

1 month ago

Journal

TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • VIM (Vimentin) • IL18 (Interleukin 18) • NLRC5 (NLR Family CARD Domain Containing 5) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3)

simvastatin

Declined RTN3 stabilizes DHCR7 to induce cholesterol-dependent tumor progression and MEK inhibitors insensitivity in thyroid cancer. (PubMed, Cell Death Dis)

Downregulation of RTN3 lead to stabilization of DHCR7 and elevate cholesterol concentration, activating EGFR/ERK pathway and contributes to progression of thyroid cancer, which can be rescued by HMG-CoA reductase inhibitor Simvastatin. We identified RTN3 as a tumor suppressor and a biomarker of sensitivity to MEK inhibitors and verified the role of cholesterol in drug resistance. The combination of statins provides a novel therapeutic method in patients resistant to MEK inhibitors.

1 month ago

Journal

DHCR7 (7-Dehydrocholesterol Reductase) • RTN3 (Reticulon 3)

simvastatin

Clinical Evaluation of Simcyp-Guided Simvastatin Dosing in Patients With Liver Cirrhosis (clinicaltrials.gov)

P4, N=22, Completed, Kafrelsheikh University

1 month ago

New P4 trial

simvastatin

ARES: Simvastatin Efficacy in ARID1A Mutated Advanced gastroESophageal Carcinoma Treated With Immunotherapy (clinicaltrials.gov)

P2, N=84, Recruiting, National Cancer Institute, Naples | Not yet recruiting --> Recruiting

1 month ago

Enrollment open

HER-2 (Human epidermal growth factor receptor 2) • ARID1A (AT-rich interaction domain 1A) • DPYD (Dihydropyrimidine Dehydrogenase)

HER-2 negative • ARID1A mutation

Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • simvastatin

2ms

Integrated transcriptomics and molecular docking identify hub genes and statin regulators in Helicobacter pylori-associated gastric mucosal pathogenesis. (PubMed, Front Cell Infect Microbiol)

To explore potential therapeutic interventions, we performed small-molecule drug prediction and molecular docking for hub genes revealed: Simvastatin: Linked to CCL20, NFKBIA, and ICAM1. Atorvastatin: Associated with CDKN1A, ICAM1, and TNF. TPCA-1: Targeting JAK1. These findings provide a theoretical foundation for further investigation into the molecular mechanisms underlying H. pylori-related diseases.

2 months ago

Journal

BRCA1 (Breast cancer 1, early onset) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • BIRC3 (Baculoviral IAP repeat containing 3) • JAK1 (Janus Kinase 1) • TNFAIP3 (TNF Alpha Induced Protein 3) • CCL20 (C-C Motif Chemokine Ligand 20) • ICAM1 (Intercellular adhesion molecule 1) • IRF1 (Interferon Regulatory Factor 1) • ITGAM (Integrin, alpha M) • SPI1 (Spi-1 Proto-Oncogene) • ETS1 (ETS Proto-Oncogene 1) • IL17A (Interleukin 17A) • STAT1 (Signal Transducer And Activator Of Transcription 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • NFKB2 (Nuclear Factor Kappa B Subunit 2) • NFKBIA (NFKB Inhibitor Alpha 2) • NFKBIE (NFKB Inhibitor Epsilon) • TRAF1 (TNF Receptor Associated Factor 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • E2F1 (E2F transcription factor 1) • EGR1 (Early Growth Response 1) • HSF1 (Heat Shock Transcription Factor 1) • JUNB (JunB Proto-Oncogene AP-1 Transcription Factor Subunit)

simvastatin • atorvastatin

2ms

KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism (clinicaltrials.gov)

P=N/A, N=12, Completed, Helsinki University Central Hospital | Not yet recruiting --> Completed

2 months ago

Trial completion

simvastatin • omeprazole

2ms

T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer (clinicaltrials.gov)

P2, N=36, Recruiting, Medical University of South Carolina | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Mar 2026 --> Mar 2027

2 months ago

Trial completion date • Trial primary completion date

simvastatin